Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

This Could Be the Next Big TSX Acquisition Target According to Analysts

Published 2021-10-13, 11:30 a/m
Updated 2021-10-13, 11:45 a/m
© Reuters.  This Could Be the Next Big TSX Acquisition Target According to Analysts

© Reuters. This Could Be the Next Big TSX Acquisition Target According to Analysts

The search for undervalued stocks is always on. Indeed, one corner of the market many investors search for value is among companies that may be an acquisition target in the near term.

Finding such companies isn’t always easy. There are certain characteristics that can make a company more prone to being acquired. However, there’s no cut-and-dried methodology for finding these acquisition target plays.

That said, Opsens (TSX:OPS), a developer, manufacturer, installer, and seller of fibre optic sensors, has been identified by analysts as a potential acquisition target. This company’s focus on fractional flow reserve (FFR), oil and gas, industrial applications, and interventional cardiology makes for a wide range of sectors covered by this company.

This industrial and medical play appears to be well positioned in its core markets. Accordingly, analysts believe this company could be targeted by companies seeking growth.

Let’s dive into why.

Opsens: A natural acquisition target A Raymond James analyst recently opined that Opsens has the potential to be a natural acquisition target of U.S. behemoth Edwards Lifesciences (NYSE:EW). This comes after Quebec-based Opsens was approved to commence the first in-vitro study with its SavvyWire transcatheter aortic valve replacement (TAVR) device. The approval came from Health Canada a few days back.

The analyst termed SavvyWire as a disruptive technology. He further said that this appears to be a transformative opportunity for the organization. Because of this, increased interest ahead of potential clearance from the U.S. Food and Drug Administration can be anticipated early in the second half of net year.

Today, maximum valve-placing guidewires used in TAVR processes are sold by Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT). However, these organizations do not account for the lion’s share of the valves utilized in TAVR. Accordingly, these companies account for roughly one-third of the total 2021 TAVR market.

Edwards Lifesciences owns the remaining 66% of the TAVR market. This market share lead may entice the company to consider Opsens as a potential acquisition to maintain this lead.

Bottom line Given the potential acquisition value placed on OPS stock, analysts have hiked their valuations on this stock. Currently, one analyst has pegged the price target for Opsens at $6 per share. To put that in perspective, this is a stock that closed last week under $3 per share.

Any stock with the potential for 100% upside over the coming year is worth considering. Indeed, this is an intriguing “special situations” play I think warrants investor attention right now on the basis of this analyst note.

The post This Could Be the Next Big TSX Acquisition Target (NYSE:TGT) According to Analysts appeared first on The Motley Fool Canada.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned.

This Article Was First Published on The Motley Fool

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.